Your browser is no longer supported. Please, upgrade your browser.
Settings
MACK Merrimack Pharmaceuticals, Inc. daily Stock Chart
MACK [NASD]
Merrimack Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.38 Insider Own0.10% Shs Outstand125.43M Perf Week6.45%
Market Cap703.66M Forward P/E- EPS next Y-0.38 Insider Trans-28.50% Shs Float119.32M Perf Month-5.08%
Income-167.10M PEG- EPS next Q-0.27 Inst Own75.30% Short Float33.91% Perf Quarter18.86%
Sales104.50M P/S6.73 EPS this Y-66.60% Inst Trans11.36% Short Ratio12.07 Perf Half Y-10.53%
Book/sh-1.76 P/B- EPS next Y69.10% ROA-96.00% Target Price9.67 Perf Year-34.08%
Cash/sh0.39 P/C14.51 EPS next 5Y5.60% ROE80.60% 52W Range4.39 - 9.02 Perf YTD-28.99%
Dividend- P/FCF- EPS past 5Y-15.50% ROI- 52W High-37.80% Beta2.01
Dividend %- Quick Ratio0.80 Sales past 5Y34.50% Gross Margin96.50% 52W Low27.79% ATR0.38
Employees426 Current Ratio1.00 Sales Q/Q71.30% Oper. Margin- RSI (14)48.93 Volatility5.51% 6.77%
OptionableYes Debt/Eq- EPS Q/Q38.60% Profit Margin- Rel Volume0.66 Prev Close5.48
ShortableYes LT Debt/Eq- EarningsNov 09 AMC Payout- Avg Volume3.35M Price5.61
Recom2.60 SMA20-6.27% SMA50-0.55% SMA200-8.70% Volume2,208,808 Change2.37%
Oct-07-16Downgrade JP Morgan Overweight → Neutral
May-27-16Initiated Robert W. Baird Neutral $8
Dec-23-15Reiterated Mizuho Buy $16 → $13
Oct-27-15Reiterated Oppenheimer Outperform $13 → $15
Apr-21-15Reiterated Mizuho Buy $13 → $16
Oct-10-14Resumed Oppenheimer Outperform $9 → $11
Jul-08-14Resumed Brean Capital Buy $16
Jun-20-14Reiterated Oppenheimer Outperform $10 → $8.50
Aug-09-13Reiterated Oppenheimer Outperform $12 → $10
Jun-25-13Initiated Mizuho Buy $12
May-08-12Initiated Oppenheimer Outperform $12
Dec-10-16 04:44PM  Is CF Corp (CFCO) A Good Stock To Buy According To Hedge Funds? at Insider Monkey
Dec-02-16 10:54AM  ETFs with exposure to Merrimack Pharmaceuticals, Inc. : December 2, 2016
Dec-01-16 07:34AM  Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MACK-US : December 1, 2016 -7.44%
Nov-26-16 05:27PM  5 Stocks Hedge Funds Hate The Most at Insider Monkey
Nov-17-16 01:04PM  MERRIMACK PHARMACEUTICALS INC Financials
Nov-11-16 08:46AM  Merrimack (MACK) Q3 Loss Lower than Expected, Stock Up
Nov-10-16 08:27AM  Merrimack May Sell or License Cancer Drug (MACK) at Investopedia +9.31%
06:36AM  Here's Why These Biopharma Stocks Soared at Least 10% Today at Motley Fool
04:20AM  Merrimack 3Q Loss $30M, or 23 Cents a Share (MACK) at Investopedia
Nov-09-16 09:28PM  Edited Transcript of MACK earnings conference call or presentation 9-Nov-16 9:30pm GMT +13.87%
04:09PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:08PM  Merrimack reports 3Q loss
04:02PM  Merrimack Reports Third Quarter 2016 Financial Results PR Newswire
09:52AM  Why Merrimack Pharmaceuticals, Inc. Shares Sank 18% Lower in October at Motley Fool
07:07AM  Q3 2016 Merrimack Pharmaceuticals Inc Earnings Release - After Market Close
Nov-08-16 08:25AM  Merrimack (MACK): What Awaits the Stock in Q3 Earnings?
Nov-04-16 08:31AM  Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MACK-US : November 4, 2016 +7.19%
Nov-02-16 04:15PM  Merrimack Announces Timing of Third Quarter 2016 Investor Conference Call PR Newswire
Nov-01-16 02:50PM  Merrimack Pharmaceuticals Inc (MACK) Sees Earnings Boost As FDA Accepts Application For Generic Drug at Insider Monkey
Oct-31-16 07:30AM  Merrimack Announces Acceptance for Review of ANDA filed by Actavis for Generic Doxorubicin Hydrochloride Liposome Injection (aka DOXIL®) PR Newswire
Oct-24-16 08:45AM  Merrimack Pharmaceuticals (MACK) Worth a Look: Stock Up 8.2%
08:17AM  Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MACK-US : October 24, 2016
Oct-19-16 12:47PM  ETFs with exposure to Merrimack Pharmaceuticals, Inc. : October 19, 2016
Oct-18-16 11:48AM  Merrimack's Cancer Drug Wins EU Nod (MACK, SHPG) at Investopedia
06:45AM  Pancreatic cancer drug developed in the Bay State approved in Europe at bizjournals.com
02:00AM  Shire Granted EU Marketing Authorization of Onivyde®, in Combination With 5-Fluorouracil (5-FU) and Leucovorin (LV),for the Treatment of Metastatic Adenocarcinoma of the Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-B PR Newswire
Oct-15-16 09:16AM  Will Positive Phase 3 Results Get Merrimack Back on Track? at Motley Fool
Oct-14-16 04:32PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Oct-13-16 04:41PM  How Risky Is Merrimack Pharmaceuticals Stock? at Motley Fool
08:23AM  Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MACK-US : October 13, 2016
Oct-12-16 09:41AM  Merrimack's Onivyde Positive in Pancreatic Cancer Study -6.65%
Oct-11-16 09:15AM  Merrimack Pharma Rises on Positive Late-Stage Results
07:30AM  Final Results of NAPOLI-1 Study Confirm Overall Survival and Progression-Free Survival Benefit for the ONIVYDE® Regimen for Patients with Metastatic Pancreatic Cancer PR Newswire
Oct-10-16 11:49AM  Why Merrimack Pharmaceuticals Inc. Rose 38% in September at Motley Fool
Oct-07-16 02:52PM  Merrimack Pharmaceuticals (MACK) Stock Drops, JPMorgan Downgrades -8.36%
07:12AM  Merrimack Pharma downgraded by JP Morgan
Oct-04-16 10:16AM  Company News for October 04, 2016
09:42AM  Merrimack Pharma's CEO Exits; Layoffs Announced at Investopedia
12:05AM  Business Watch at The Wall Street Journal
Oct-03-16 04:36PM  Janus Capital and Cabela's soar; Merrimack Pharma sinks
02:58PM  Merrimack Pharmaceuticals lays off 22% of workforce; CEO steps down at bizjournals.com
02:17PM  Merrimack CEO resigns, company cuts 22 percent of workforce
01:00PM  Corporate Rejig At Merrimack To Save $200M (MACK) at Investopedia
12:59PM  Heres Why TASER International, Heron Therapeutics and Three Other Stocks Are Trading Lower on Monday at Insider Monkey
10:41AM  Merrimack Pharmaceuticals (MACK) Stock Drops, CEO Mulroy Resigns
09:24AM  [$$] Merrimack Pharmaceuticals Cuts Jobs; CEO Resigns at The Wall Street Journal
09:17AM  Morning Movers: Janus Soars On Merger; Tesla Doubles 3Q Sales at Barrons.com
07:39AM  Merrimack Pharmaceuticals CEO resigns as company cuts 22% of workforce at MarketWatch
07:33AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Notice of Delist
07:15AM  Merrimack Announces Major Corporate Restructuring PR Newswire
Sep-29-16 09:44AM  ETFs with exposure to Merrimack Pharmaceuticals, Inc. : September 29, 2016
Sep-28-16 04:09PM  Merrimack to Present Final Results of Phase 3 NAPOLI-1 Study at the European Society for Medical Oncology 2016 Congress PR Newswire
Sep-26-16 12:55PM  Bullish and Bearish Reversals for the Week
Sep-13-16 04:38PM  Cash Dwindles as Merrimack Fights Cancer (MACK) at Investopedia
Sep-12-16 11:17AM  ETFs with exposure to Merrimack Pharmaceuticals, Inc. : September 12, 2016 +6.07%
07:54AM  Why Merrimack Pharmaceuticals Inc Fell 20.3% in August at Motley Fool
Sep-06-16 04:04PM  Ericsson, Merrimack Drop Into Tuesdays 52-Week Low Club at 24/7 Wall St.
Sep-02-16 10:11AM  ETFs with exposure to Merrimack Pharmaceuticals, Inc. : September 2, 2016
Aug-26-16 04:04PM  Noble Corp., Express Stay in 52-Week Low Club Again Friday at 24/7 Wall St.
Aug-25-16 04:04PM  Express, Noble Corp. Lead Thursdays 52-Week Low Club at 24/7 Wall St.
Aug-24-16 07:08AM  7 Stocks Under $10 Making Big Up Moves -7.59%
Aug-22-16 11:41AM  ETFs with exposure to Merrimack Pharmaceuticals, Inc. : August 22, 2016
Aug-10-16 12:01PM  Merrimack Pharmaceuticals, Inc. :MACK-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016
Aug-09-16 01:49PM  ETFs with exposure to Merrimack Pharmaceuticals, Inc. : August 9, 2016
Aug-08-16 08:28AM  Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MACK-US : August 8, 2016
Aug-05-16 04:08PM  Edited Transcript of MACK earnings conference call or presentation 4-Aug-16 8:30pm GMT -6.76%
04:02PM  Merrimack (MACK) Q2 Loss Wider than Expected, Sales Top
Aug-04-16 06:17PM  Merrimack reports 2Q loss
04:13PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:01PM  Merrimack Reports Second Quarter 2016 Financial Results PR Newswire
07:07AM  Q2 2016 Merrimack Pharmaceuticals Inc Earnings Release - After Market Close
Aug-01-16 06:38PM  Merrimack (MACK): Can the Stock Surprise in Q2 Earnings?
Jul-29-16 12:47PM  ETFs with exposure to Merrimack Pharmaceuticals, Inc. : July 29, 2016
Jul-25-16 02:01AM  Merrimack Announces ONIVYDE® Regimen Receives Positive CHMP Opinion in European Union PR Newswire
02:00AM  ONIVYDE® Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Following Gemcitabine Based Therapy PR Newswire
Jul-19-16 04:05PM  Merrimack Announces Timing of Second Quarter 2016 Investor Conference Call PR Newswire
Jul-18-16 06:45PM  Celgene's Revlimid Gains EU Nod for Mantle Cell Lymphoma
Jul-15-16 10:36AM  Gilead's HCV Drug Epclusa Gets Regulatory Nod in Canada +5.08%
09:51AM  Ultragenyx (RARE) Reports Positive Phase III rhGUS Data
Jul-13-16 04:06PM  Bayer Expands Drug Discovery Collaboration with X-Chem -5.80%
12:33PM  Merrimack Pharmaceuticals Stock Sank Like a Stone in June at Motley Fool
08:15AM  BioDelivery Sciences (BDSI) Catches Eye: Stock Rises 12%
07:07AM  CytRx (CYTR) Stock Falls on Unfavorable Aldoxorubicin Data
05:46AM  Comeback for Juno (JUNO) Stock? FDA Lifts Clinical Hold
Jul-07-16 06:22PM  Merrimack Stock Up on Fast Track Status for Seribantumab
Jul-06-16 08:00AM  FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer PR Newswire
Jul-05-16 12:07PM  Buy 5 Attractive Biotechs at Bargain Prices
Jun-30-16 08:00AM  NAPOLI-1 Data Demonstrates ONIVYDE® Regimen Maintains Quality of Life While Improving Overall Survival in Patients with Metastatic Pancreatic Cancer PR Newswire
Jun-27-16 04:09PM  Here's Why Merrimack Pharmaceuticals' Stock Has Been Getting Crushed in 2016 at Motley Fool -7.36%
Jun-22-16 08:07AM  The Quest for an Effective Treatment for Pancreatic Cancer
Jun-21-16 04:32PM  Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on Gastrointestinal Cancer PR Newswire
Jun-16-16 04:56PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-09-16 09:30AM  The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics -5.20%
Jun-08-16 10:52AM  Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Jun-07-16 04:57PM  Merrimack Announces Positive Data on Oncology Candidate
Jun-06-16 07:30AM  Final Analysis of First-in-Human Phase 1 Study of MM-151 Shows Positive Clinical Activity in Multiple Solid Tumor Types, Including Colorectal Cancer PR Newswire
Jun-03-16 07:55AM  These 7 Stocks Under $10 Are About to Break Out
May-20-16 02:37PM  Merrimack/Baxalta Start Study on Colorectal Cancer Drug
May-19-16 07:40PM  ETFs with exposure to Merrimack Pharmaceuticals, Inc. : May 19, 2016
02:20PM  Targeting cancer
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company's therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stewart Edward J.Head of CommercialJul 26Option Exercise2.4730,00074,10051,385Jul 27 04:51 PM
Schoeberl Birgit M.Head of DiscoveryJul 25Option Exercise2.1250,000106,000115,657Jul 27 04:48 PM
Schoeberl Birgit M.Head of DiscoveryJul 25Sale5.5050,000275,00065,657Jul 27 04:48 PM
PORTER MICHAEL EDirectorMar 17Buy7.205,00036,000754,448Mar 21 09:25 AM
PORTER MICHAEL EDirectorMar 15Buy7.655,00038,250749,448Mar 17 10:51 AM
PORTER MICHAEL EDirectorMar 08Buy7.0910,00070,900744,448Mar 10 09:28 AM
PORTER MICHAEL EDirectorMar 03Buy6.2710,00062,700734,448Mar 04 09:02 AM
PORTER MICHAEL EDirectorMar 02Buy6.635,00033,150724,448Mar 04 09:02 AM
PORTER MICHAEL EDirectorMar 01Buy6.6010,00066,000719,448Mar 02 11:13 AM
PORTER MICHAEL EDirectorFeb 29Buy5.6110,00056,100709,448Mar 02 11:13 AM
Lee Vivian SDirectorFeb 29Buy5.5035,000192,50065,000Feb 29 02:57 PM
McClements William M.Head of Corporate OperationsFeb 29Buy5.722,00011,44014,072Mar 01 01:54 PM
Stewart Edward J.Head of CommercialJan 05Option Exercise1.814,0007,24025,385Jan 07 06:41 PM
Stewart Edward J.Head of CommercialJan 05Sale8.004,00032,00021,385Jan 07 06:41 PM